Regeneron Slides as New Wet AMD Trial Data Raises Fresh Eylea Competition Concerns

Regeneron Pharmaceuticals (REGN) is down 4.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is fresh competitive pressure on Regeneron’s Eylea franchise after a rival eye-drug developer posted positive pivotal data in wet age-related macular degeneration. That appears to have revived investor concerns that Eylea and Eylea HD could face even more pricing and market-share pressure in a business that is already dealing with biosimilars and other competition.

Details:

Kodiak Sciences announced that two drug candidates in its DAYBREAK Phase 3 wet AMD study met primary endpoints against aflibercept, the molecule sold by Regeneron as Eylea.

One of those candidates was described as showing a potential new standard-of-care profile, including a majority of patients reaching 24-week dosing intervals, which may have sharpened investor focus on future retinal-market competition.

Regeneron had already warned in its second-quarter 2026 update that Eylea sales were being pressured by lower demand, lower net selling prices, and continued competitive dynamics as patients transition toward Eylea HD.

Regeneron also said it expects continued biosimilar competition for Eylea, so a strong late-stage readout from another retinal challenger could have added to worries about the franchise outlook.

Sources:

Kodiak Sciences, Regeneron Pharmaceuticals, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$REGN Insider Trading Activity

$REGN insiders have traded $REGN stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.

Here’s a breakdown of recent trading of $REGN stock by insiders over the last 6 months:

MARION MCCOURT (EVP Commercial) has made 0 purchases and 2 sales selling 2,346 shares for an estimated $2,002,458.
KATHRYN GUARINI has made 0 purchases and 2 sales selling 800 shares for an estimated $660,000.
HUDA Y ZOGHBI sold 800 shares for an estimated $640,000
ARTHUR F RYAN has made 0 purchases and 13 sales selling 300 shares for an estimated $200,553.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive REGN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$REGN Hedge Fund Activity

We have seen 600 institutional investors add shares of $REGN stock to their portfolio, and 798 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 3,774,199 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,353,364,044
INVESCO LTD. added 2,216,187 shares (+128.5%) to their portfolio in Q2 2026, for an estimated $1,381,881,241
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 846,306 shares (+inf%) to their portfolio in Q2 2026, for an estimated $527,705,643
FMR LLC removed 686,228 shares (-45.2%) from their portfolio in Q2 2026, for an estimated $427,890,607
PRICE T ROWE ASSOCIATES INC /MD/ removed 647,818 shares (-29.8%) from their portfolio in Q2 2026, for an estimated $403,940,435
CAPITAL WORLD INVESTORS removed 604,075 shares (-42.6%) from their portfolio in Q2 2026, for an estimated $376,664,925
WELLINGTON MANAGEMENT GROUP LLP removed 567,372 shares (-30.9%) from their portfolio in Q2 2026, for an estimated $353,779,136

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$REGN Congressional Stock Trading

Members of Congress have traded $REGN stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 05/15.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$REGN Analyst Ratings

Wall Street analysts have issued reports on $REGN in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HSBC issued a "Buy" rating on 07/06/2026
Barclays issued a "Overweight" rating on 04/30/2026
Truist Securities issued a "Buy" rating on 04/30/2026

To track analyst ratings and price targets for $REGN, check out Quiver Quantitative's $REGN forecast page.

$REGN Price Targets

Multiple analysts have issued price targets for $REGN recently. We have seen 17 analysts offer price targets for $REGN in the last 6 months, with a median target of $769.0.

Here are some recent targets:

Biren Amin from Piper Sandler set a target price of $854.0 on 07/09/2026
Matthew Harrison from Morgan Stanley set a target price of $730.0 on 07/08/2026
Gregory Renza from Truist Securities set a target price of $769.0 on 07/07/2026
Robert Wasserman from Benchmark set a target price of $185.0 on 07/07/2026
Brian Abrahams from RBC Capital set a target price of $696.0 on 07/07/2026
Carter Gould from Cantor Fitzgerald set a target price of $750.0 on 07/06/2026
Rajesh Kumar from HSBC set a target price of $880.0 on 07/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.